Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study

Table 4 Efficacy in Patients With at Least 2 Types of Previous Treatment^a

Endpoint	DEX 0.7	Sham	Mean Difference
Endpoint	n = 61	n = 57	(95 % CI)
Patients with BCVA ≥15-letter improvement from baseline at study end, %	26.2	8.8	17.5 (4.2, 30.7)^c
Mean BCVA average change during the study, letters^b	4.0	−0.3	3.8 (1.1, 6.5)^d
Mean CRT average change during the study, μm^b	−108	−26	−111 (−154, −69)^d

^aTypes of previous treatment were macular laser, intravitreal triamcinolone acetonide, and intravitreal anti-VEGF
^bArea-under-the-curve approach
^cBased on the Cochran-Mantel-Haenszel general association test stratified by study
^dBased on an analysis of covariance model with treatment and study as factors and the baseline value as a covariate
BCVA best-corrected visual acuity, CI confidence interval, CRT central retinal thickness, DEX 0.7 dexamethasone intravitreal implant 0.7 mg, VEGF vascular endothelial growth factor

ISSN: 1471-2415